Further, K12 CAR-T cells effectively eliminated CD7-positive tumor cell lines as well as primary patient-derived CD7-positive T-ALL and AML in vitro and had prominent anti-leukemic activity in an intravenously (i.v.)injected leukemia xenograft mouse model, with complete remission in 60% of mice. This evidence concerns the gene SECTM1 and acute myeloid leukemia.